ChromaDex Appoints New CSO, Adds Director

Ticker: NAGE · Form: 8-K · Filed: Sep 20, 2024 · CIK: 1386570

Chromadex Corp. 8-K Filing Summary
FieldDetail
CompanyChromadex Corp. (NAGE)
Form Type8-K
Filed DateSep 20, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.001, $400,000, $360,000
Sentimentneutral

Sentiment: neutral

Topics: executive-appointment, board-of-directors, personnel-change

Related Tickers: CDXC

TL;DR

CDXC beefs up leadership with a new CSO and a board member.

AI Summary

ChromaDex Corp. announced on September 19, 2024, the appointment of Dr. Robert H. Eckman as Chief Scientific Officer and the election of Ms. Sarah E. McSweeney to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, though specific dollar amounts for these arrangements were not detailed in this filing.

Why It Matters

These executive and board changes could signal a strategic shift or a strengthening of leadership in scientific and governance areas for ChromaDex.

Risk Assessment

Risk Level: low — The filing primarily concerns executive appointments and board changes, which are routine corporate governance events and do not inherently present immediate financial risks.

Key Players & Entities

  • ChromaDex Corp. (company) — Registrant
  • Dr. Robert H. Eckman (person) — Appointed Chief Scientific Officer
  • Ms. Sarah E. McSweeney (person) — Elected to Board of Directors
  • September 19, 2024 (date) — Date of Report

FAQ

Who has been appointed as the new Chief Scientific Officer for ChromaDex Corp.?

Dr. Robert H. Eckman has been appointed as the new Chief Scientific Officer.

Who has been elected to the Board of Directors of ChromaDex Corp.?

Ms. Sarah E. McSweeney has been elected to the Board of Directors.

What is the date of this Form 8-K filing?

The date of this Form 8-K filing is September 19, 2024.

What other item information is included in this filing besides executive changes?

This filing also includes information on compensatory arrangements of certain officers and financial statements and exhibits.

In which state was ChromaDex Corp. incorporated?

ChromaDex Corp. was incorporated in Delaware.

Filing Stats: 985 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2024-09-20 08:32:40

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share CDXC The Nasdaq Capital Mar
  • $400,000 — l Officer: (i) an annual base salary of $400,000, (ii) a discretionary target annual bon
  • $360,000 — , having an initial grant date value of $360,000 and with an exercise price equal to the

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 10.1 Offer Letter, dated September 10, 2024, by and between Ozan Pamir and ChromaDex, Inc. 99.1 Press Release dated September 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CHROMADEX CORPORATION Dated: September 20, 2024 By: /s/ Robert Fried Name: Robert Fried Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.